Literature DB >> 30401435

Microbially Produced Imidazole Propionate Impairs Insulin Signaling through mTORC1.

Ara Koh1, Antonio Molinaro1, Marcus Ståhlman1, Muhammad Tanweer Khan1, Caroline Schmidt2, Louise Mannerås-Holm1, Hao Wu1, Alba Carreras1, Heeyoon Jeong3, Louise E Olofsson1, Per-Olof Bergh1, Victor Gerdes4, Annick Hartstra5, Maurits de Brauw4, Rosie Perkins1, Max Nieuwdorp6, Göran Bergström2, Fredrik Bäckhed7.   

Abstract

Interactions between the gut microbiota, diet, and the host potentially contribute to the development of metabolic diseases. Here, we identify imidazole propionate as a microbially produced histidine-derived metabolite that is present at higher concentrations in subjects with versus without type 2 diabetes. We show that imidazole propionate is produced from histidine in a gut simulator at higher concentrations when using fecal microbiota from subjects with versus without type 2 diabetes and that it impairs glucose tolerance when administered to mice. We further show that imidazole propionate impairs insulin signaling at the level of insulin receptor substrate through the activation of p38γ MAPK, which promotes p62 phosphorylation and, subsequently, activation of mechanistic target of rapamycin complex 1 (mTORC1). We also demonstrate increased activation of p62 and mTORC1 in liver from subjects with type 2 diabetes. Our findings indicate that the microbial metabolite imidazole propionate may contribute to the pathogenesis of type 2 diabetes.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  IRS; histidine; imidazole propionate; mTORC1; microbiome; p38γ; p62

Mesh:

Substances:

Year:  2018        PMID: 30401435     DOI: 10.1016/j.cell.2018.09.055

Source DB:  PubMed          Journal:  Cell        ISSN: 0092-8674            Impact factor:   41.582


  166 in total

Review 1.  What Should I Eat and Why? The Environmental, Genetic, and Behavioral Determinants of Food Choice: Summary from a Pennington Scientific Symposium.

Authors:  Emily Qualls-Creekmore; Kara L Marlatt; Esther Aarts; Annadora Bruce-Keller; Tim S Church; Karine Clément; Jennifer O Fisher; Penny Gordon-Larsen; Christopher D Morrison; Helen E Raybould; Donna H Ryan; Philip R Schauer; Alan C Spector; Maartje S Spetter; Garret D Stuber; Hans-Rudolf Berthoud; Eric Ravussin
Journal:  Obesity (Silver Spring)       Date:  2020-06-10       Impact factor: 5.002

2.  Nanosilver Mitigates Biofilm Formation via FapC Amyloidosis Inhibition.

Authors:  Zil-E Huma; Ibrahim Javed; Zhenzhen Zhang; Hajira Bilal; Yunxiang Sun; Syed Zajif Hussain; Thomas P Davis; Daniel E Otzen; Cornelia B Landersdorfer; Feng Ding; Irshad Hussain; Pu Chun Ke
Journal:  Small       Date:  2020-01-27       Impact factor: 13.281

3.  Type 2 diabetes: Microbial metabolite impairs insulin signaling.

Authors:  Sarah Crunkhorn
Journal:  Nat Rev Drug Discov       Date:  2018-11-28       Impact factor: 84.694

4.  Metabolomics reveals elevated urinary excretion of collagen degradation and epithelial cell turnover products in irritable bowel syndrome patients.

Authors:  Mai Yamamoto; Maria Ines Pinto-Sanchez; Premysl Bercik; Philip Britz-McKibbin
Journal:  Metabolomics       Date:  2019-05-20       Impact factor: 4.290

5.  Weak Microbial Metabolites: a Treasure Trove for Using Biomimicry to Discover and Optimize Drugs.

Authors:  Zdenek Dvorak; Max Klapholz; Thomas P Burris; Benjamin P Willing; Antimo Gioiello; Roberto Pellicciari; Francesco Galli; John March; Stephen J O'Keefe; R Balfour Sartor; Chang H Kim; Maayan Levy; Sridhar Mani
Journal:  Mol Pharmacol       Date:  2020-08-06       Impact factor: 4.436

Review 6.  Gut microbial metabolites as multi-kingdom intermediates.

Authors:  Kimberly A Krautkramer; Jing Fan; Fredrik Bäckhed
Journal:  Nat Rev Microbiol       Date:  2020-09-23       Impact factor: 60.633

Review 7.  Gut microbiota in human metabolic health and disease.

Authors:  Yong Fan; Oluf Pedersen
Journal:  Nat Rev Microbiol       Date:  2020-09-04       Impact factor: 60.633

8.  Xenometabolite signatures in the UC Davis type 2 diabetes mellitus rat model revealed using a metabolomics platform enriched with microbe-derived metabolites.

Authors:  Kelly E Mercer; Laxmi Yeruva; Lindsay Pack; James L Graham; Kimber L Stanhope; Sree V Chintapalli; Umesh D Wankhade; Kartik Shankar; Peter J Havel; Sean H Adams; Brian D Piccolo
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2020-06-08       Impact factor: 4.052

9.  Amyotrophic lateral sclerosis and intestinal microbiota-toward establishing cause and effect.

Authors:  Marc Gotkine; Denise Kviatcovsky; Eran Elinav
Journal:  Gut Microbes       Date:  2020-06-05

Review 10.  Microbiota in cerebrovascular disease: A key player and future therapeutic target.

Authors:  Shuichi Tonomura; Masafumi Ihara; Robert P Friedland
Journal:  J Cereb Blood Flow Metab       Date:  2020-04-20       Impact factor: 6.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.